Can High-Flow oxygen at home prevent COPD Flare-Ups?
NCT ID NCT05196698
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether using high-flow oxygen at home can reduce severe COPD attacks or death in 406 patients who have just been hospitalized for a flare-up. Participants receive either high-flow oxygen or standard oxygen therapy. The goal is to see if high-flow oxygen helps them stay out of the hospital longer.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- High Flow Oxygen Therapy
- What this could lead to
- If it works, this could offer a new way to prevent serious COPD attacks and improve quality of life at home.
- What could go wrong
- This is an early-stage study with no phase, so results are uncertain. The treatment may not reduce hospital visits or death more than standard oxygen.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 406 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2022
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patient with a diagnosis of COPD defined by GOLD guidelines 2. Admitted in hospital for AECOPD 3. With severe respiratory impairment defined by one of the following criteria (long-term oxygen therapy (LTOT) criteria): * Previously established on long-term oxygen therapy according to the following criteria: PaO2 \< 7.3kPa or \<8kPa with polycythemia, pulmonary hypertension or right heart failure on room air in stable condition Or * PaO2 \< 7.3kPa or \<8kPa with polycythemia, pulmonary hypertension or right heart failure on room air after clinical stabilization during the index admission 4. Patients affiliated or, beneficiary of a social security cover 5. Patient who has read and understood the information letter and signed the consent form 6. For woman of childbearing potential, use of an effective contraception (oestro-progestatives or intra-uterine device or tubal ligation) since at least 1 month and an blood pregnancy test by β-HCG negative at the screening visit, during the duration of the study 7. For menopausal woman: confirmatory diagnosis (amenorrhea not medically induced for at least 12 months before the inclusion visit) Exclusion Criteria: 1. Age \<18 or \> 85 years 2. Patient treated with chronic NIV with ongoing treatment 3. Patients diagnosed with obstructive sleep apnea (OSA) treated with CPAP. Diagnosis of OSA will be over-ruled in patient that had a previous overnight polygraphy. For patients who never had an overnight polygraphy, screening for OSA will be made using the STOP-BANG questionnaire. If the results of the STOP-BANG questionnaire (Appendix 1) is \>3, an Apnea-link recording will be performed. If AHI\>30/h, patient will be excluded. 4. BMI \> 35 kg/m2 5. Patient admitted for an acute COVID-19 infection 6. Hypercapnic respiratory failure justifying NIV defined as 1. An Arterial Blood Gas (ABG) PaCO2 \> 7 kPa in stable condition within 6 months 2. Patients with ABG PaCO2 \> 7 kPa at hospital discharge and that remained hypercapnic between 2- and 4-weeks following discharge 7. Pregnancy (blood pregnancy test positive) or lactation ongoing 8. Significant psychiatric disorder or dementia that would prevent adherence to study protocol 9. Tobacco use \< 10 pack-year 10. Expected survival \< 12 months due to any situation other than COPD disease 11. Refusal of high-flow oxygen therapy 12. Person deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision) 13. Patients already involved in a research protocol that would impact with the outcome measured in the current protocol
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
UHRouen
RECRUITINGRouen, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a COPD flare stun the heart? study watches for hidden strain
- Can better training get doctors to talk about what matters most to dying veterans?
- Can an injected antibody calm inflamed lungs and cut COPD flare-ups?
- Detailed lung scans could map COPD damage more precisely
- Can AI help nurses guide At-Risk seniors to better care and lower costs?
- Fine-Mist inhalers aim to reach deep lungs in COPD